Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship
Published: March 11, 2024
- Hematopoietic stem cell transplantation (HSCT) can cure various disorders but poses cardiovascular (CV) risks, especially for older patients and those with CV diseases. Cardiovascular evaluations are crucial in pre-transplant assessments, but guidelines are lacking.
- This statement summarizes the data on transplant-related complications and provides guidance for CV management throughout the HSCT process.
- Long-term CV management of HSCT survivors includes optimizing risk factors, monitoring, and maintaining a low threshold for evaluating CV causes of symptoms.
Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation
Salim Hayek, MD, a cardiovascular specialist in cardio-oncology from the UTMB Health is joined by Amelia Langston, MD, a hematology and medical oncology specialist from Emory University to discuss their new AHA scientific statement on the cardiovascular management of patients undergoing hematopoietic stem cell transplantation (HSCT). They review the phases of HCST, the incidence of cardiovascular complications, long-term management, and the significance of survivorship post-transplant.
Supporting Materials
Recommended Reading
- Cancer Therapy–Related Hypertension
- Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology
- Preclinical Models of Cancer Therapy–Associated Cardiovascular Toxicity
- Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors
- Use of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing